Haisco Pharmaceutical Group Co., Ltd. (SHE:002653)

SHE:002653 Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020
Operating Revenue	4,003	3,693	3,335	2,998	2,765	3,328
Other Revenue	32.3	28.6	19.94	17.03	8.46	2.08
Revenue	4,036	3,721	3,355	3,015	2,773	3,330
Revenue Growth (YoY)	9.90%	10.92%	11.27%	8.72%	-16.71%	-15.43%
Cost of Revenue	1,129	1,062	971.25	925.27	946.88	1,068
Gross Profit	2,906	2,660	2,384	2,090	1,826	2,262
Selling, General & Admin	1,908	1,763	1,521	1,464	1,331	1,586
Research & Development	751.26	624.13	516.67	447.87	431.4	405.53
Other Operating Expenses	79.85	8.6	13.98	35.82	26.28	42.69
Operating Expenses	2,740	2,398	2,052	1,948	1,789	2,034
Operating Income	166.26	262.03	331.58	141.57	37.6	228.35
Interest Expense	-36.35	-37.84	-42.28	-50.91	-27.16	-27.29
Interest & Investment Income	140.47	140.71	19.33	235.41	426.35	301.58
Currency Exchange Gain (Loss)	0.45	0.76	-0.06	0.97	-0.17	-2.43
Other Non Operating Income (Expenses)	7.5	-1.81	-0.63	1.13	-1.1	-7.1
EBT Excluding Unusual Items	278.33	363.84	307.93	328.16	435.52	493.1
Gain (Loss) on Sale of Investments	24.12	0.08	-60.47	-	-	-
Gain (Loss) on Sale of Assets	6	31.1	-0.28	-0	-0.13	0.33
Asset Writedown	-29.92	-83.19	-13.02	-0.84	-0.62	-18.79
Other Unusual Items	134.8	151.12	68.37	39.3	75.97	214.8
Pretax Income	413.32	462.95	302.52	366.61	510.74	689.45
Income Tax Expense	-18.68	-3.25	6.96	-25.1	-6.84	88.25
Earnings From Continuing Operations	432	466.2	295.56	391.71	517.58	601.2
Minority Interest in Earnings	-72.44	-70.74	-0.45	-114.64	-172.52	35.42
Net Income	359.56	395.46	295.11	277.07	345.06	636.62
Net Income to Common	359.56	395.46	295.11	277.07	345.06	636.62
Net Income Growth	-6.55%	34.00%	6.51%	-19.70%	-45.80%	28.90%
Shares Outstanding (Basic)	1,118	1,130	1,093	1,066	1,078	1,079
Shares Outstanding (Diluted)	1,118	1,130	1,093	1,066	1,078	1,079
Shares Change (YoY)	2.60%	3.37%	2.57%	-1.17%	-0.07%	0.50%
EPS (Basic)	0.32	0.35	0.27	0.26	0.32	0.59
EPS (Diluted)	0.32	0.35	0.27	0.26	0.32	0.59
EPS Growth	-8.92%	29.63%	3.85%	-18.75%	-45.76%	28.26%
Free Cash Flow	209.85	1.39	58.57	-605.62	-667.14	-395.51
Free Cash Flow Per Share	0.19	0.00	0.05	-0.57	-0.62	-0.37
Dividend Per Share	0.270	0.415	0.200	-	0.185	0.372
Dividend Growth	-21.74%	107.50%	-	-	-50.22%	304.35%
Gross Margin	72.02%	71.47%	71.05%	69.31%	65.86%	67.93%
Operating Margin	4.12%	7.04%	9.88%	4.70%	1.36%	6.86%
Profit Margin	8.91%	10.63%	8.80%	9.19%	12.44%	19.12%
Free Cash Flow Margin	5.20%	0.04%	1.75%	-20.09%	-24.06%	-11.88%
EBITDA	408.7	498.35	544.25	317.33	183.93	332.93
EBITDA Margin	10.13%	13.39%	16.22%	10.52%	6.63%	10.00%
D&A For EBITDA	242.43	236.32	212.67	175.76	146.33	104.59
EBIT	166.26	262.03	331.58	141.57	37.6	228.35
EBIT Margin	4.12%	7.04%	9.88%	4.70%	1.36%	6.86%
Effective Tax Rate	-	-	2.30%	-	-	12.80%
Revenue as Reported	4,036	3,721	3,355	3,015	2,773	3,330
Advertising Expenses	-	-	-	-	3.74	6.74

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.